Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 6,410,000 shares, a growth of 43.1% from the November 30th total of 4,480,000 shares. Based on an average daily volume of 949,600 shares, the days-to-cover ratio is presently 6.8 days. Currently, 13.6% of the company's shares are short sold.

Insiders Place Their Bets

In other Janux Therapeutics news, CEO David Alan Campbell sold 25,000 shares of the firm's stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total value of $1,404,750.00. Following the completion of the sale, the chief executive officer now directly owns 217,054 shares in the company, valued at approximately $12,196,264.26. This trade represents a 10.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of the business's stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $50.02, for a total value of $92,186.86. Following the completion of the sale, the insider now directly owns 6,371 shares of the company's stock, valued at $318,677.42. The trade was a 22.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 91,843 shares of company stock worth $5,130,437. 29.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Large investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. lifted its holdings in Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company's stock valued at $937,000 after purchasing an additional 7,442 shares during the last quarter. Virtu Financial LLC lifted its stake in shares of Janux Therapeutics by 48.0% during the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock valued at $339,000 after buying an additional 2,419 shares in the last quarter. Neo Ivy Capital Management bought a new position in Janux Therapeutics in the 3rd quarter worth approximately $940,000. Geode Capital Management LLC grew its stake in Janux Therapeutics by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company's stock valued at $30,107,000 after buying an additional 38,490 shares in the last quarter. Finally, Barclays PLC raised its holdings in Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock valued at $7,907,000 after acquiring an additional 144,883 shares during the period. Hedge funds and other institutional investors own 75.39% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on JANX shares. HC Wainwright raised their price objective on shares of Janux Therapeutics from $63.00 to $70.00 and gave the company a "buy" rating in a research note on Tuesday, December 3rd. Leerink Partnrs raised Janux Therapeutics to a "strong-buy" rating in a research note on Friday, November 22nd. UBS Group started coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a "buy" rating and a $69.00 target price on the stock. BTIG Research raised their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday, December 3rd. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research note on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $89.90.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock traded down $1.60 on Monday, reaching $52.50. 604,071 shares of the company traded hands, compared to its average volume of 783,549. The company has a 50 day moving average of $54.43 and a 200 day moving average of $47.50. Janux Therapeutics has a 52 week low of $7.79 and a 52 week high of $71.71. The firm has a market capitalization of $2.76 billion, a PE ratio of -44.87 and a beta of 3.29.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Janux Therapeutics's revenue for the quarter was down 82.6% compared to the same quarter last year. As a group, analysts anticipate that Janux Therapeutics will post -1.35 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.